---
schema_version: "secwatch.filing_event.v1"
accession: "0001339970-25-000016"
form_type: "8-K/A"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:12:30.390018+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma Phase 3 EFZO-FIT topline due mid-Sept; Q2 cash $83.2M, raised $30.7M ATM

## Summary
- Completed last patient visit in Phase 3 EFZO-FIT study for pulmonary sarcoidosis; topline results expected mid-September 2025.
- Interim Phase 2 data in SSc-ILD showed stable/improved mRSS in diffuse patients; no treatment-related serious adverse events.
- ATYR0101 advanced to IND candidate for pulmonary fibrosis; IND filing planned in H2 2026.
- Cash, equivalents and investments $83.2M at June 30, 2025; raised ~$30.7M in ATM offering after quarter-end.
- R&D expenses $15.4M, G&A $4.9M for Q2 2025; cash runway sufficient for one year after Phase 3 readout.

## SEC filing metadata
- accession: 0001339970-25-000016
- form_type: 8-K/A
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01, 2.06
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000133997025000016/0001339970-25-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000133997025000016/atyr-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001339970-25-000016
- JSON: https://secwatch.observer/filing/0001339970-25-000016.json
- Plain text: https://secwatch.observer/filing/0001339970-25-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.